IDEAYA Biosciences Reveals Clearance Of Investigational New DrugApplication With FDA For Initiation Of Phase 1 Clinical Trial To Evaluate Werner Helicase Development Candidate IDE275
IDEAYA Biosciences Reveals Clearance Of Investigational New DrugApplication With FDA For Initiation Of Phase 1 Clinical Trial To Evaluate Werner Helicase Development Candidate IDE275
ideaya生物科學透露已獲得FDA對Werner螺旋酶發展候選藥物IDE275進行階段1臨床試驗啓動的新藥申請清關審批。
IDE275 (GSK959) has demonstrated robust and selective synthetic lethality preclinically in the high microsatellite instability (MSI-High) biomarker setting, and the Phase 1 clinical trial will enroll patients having tumors characterized by MSI-High.
IDE275（GSK959）在高微衛星不穩定性（MSI-High）生物標誌物設置中在臨床前表現出強大和選擇性的合成致死性，第1階段臨床試驗將招募具有MSI-High特徵的腫瘤患者。
IDEAYA to receive a $7 million payment for IND acceptance, and potential future aggregate milestones of up to $950 million. IDEAYA has a 50/50 US Profit Share and an 80/20 (GSK/IDEAYA) global research and development cost share
IDEAYA將收到700萬美元的IND接受費，並有高達95000萬美元的潛在未來累計里程碑。IDEAYA享有50/50的美國利潤分享和全球研發成本50/50的光收入分享（GSK/IDEAYA）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間